Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00198276 · ClinicalTrials.gov registry record · Phase 4
Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer
A Phase 4 study of Cancer, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT00198276: Completed Phase 4 study of Cancer, sponsored by Inovio Pharmaceuticals.
NCT00198276 is a Phase 4 study of Cancer that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 88 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00198276, a Phase 4 study of Cancer, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to study the safety and efficacy of MedPulser Electroporation with bleomycin treatment of cutaneous and subcutaneous foci of cancer.
Conditions Studied
Interventions
- COMBINATION_PRODUCT MedPulser Electroporation with bleomycin
Study Locations (1)
California
- Inovio Biomedical Corporation - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2004-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00198276 record still lists
NCT00198276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which MedPulser Electroporation with bleomycin is the first listed.
NCT00198276 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00198276 about?
NCT00198276 is a clinical study titled "Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer". The purpose of the study is to study the safety and efficacy of MedPulser Electroporation with bleomycin treatment of cutaneous and subcutaneous foci of cancer.
What is the current status of trial NCT00198276?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2004-02. Estimated completion is 2008-09.
What conditions does trial NCT00198276 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT00198276?
The interventions under investigation include: MedPulser Electroporation with bleomycin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT00198276?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00198276 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00198276's enrollment target sits among peer trials
88 340th of 615 higher than 275 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The STOP-MED CTRCD Trial
RECRUITING · Phase 4
-
Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
COMPLETED · Phase 4
-
Tobacco Treatment Comparison for Cancer Care
COMPLETED · Phase 4
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia